[Peripheral neuropathy with monoclonal gammopathy]

Area of Science:

• Neurology
• Immunology
• Oncology

Background:

• Paraproteinemia, the presence of abnormal proteins in the blood, is associated with various peripheral neuropathies.
• Understanding the specific type of paraprotein and its clinical presentation is crucial for diagnosis and management.
• Different paraprotein types (IgM, IgG, IgA) are linked to distinct patterns of polyneuropathy (PN).

Observation:

• A patient with IgM-kappa paraproteinemia presented with polyneuropathy (PN) characterized by very slow nerve conduction velocities.
• Demyelinating PN with IgM-kappa paraprotein often suggests monoclonal gammopathy of undetermined significance (MGUS) or macroglobulinemia.
• IgG-lambda or IgA-lambda paraproteinemia is frequently seen in osteosclerotic myeloma, a treatable condition.
• Small fiber neuropathy, involving pain, temperature, and autonomic dysfunction, is characteristic of systemic amyloidosis or related conditions.
• Mild sensorimotor axonal polyneuropathy is a non-specific finding across various gammopathies.
• Distinguishing paraproteinemic PN from paraneoplastic sensory polyneuropathy is clinically important.
• Paraproteinemias can mimic motor neuron diseases like amyotrophic lateral sclerosis (ALS) but may progress slower with subclinical sensory nerve involvement.
• Mononeuropathy or multifocal neuropathy associated with monoclonal proteins is often indicative of cryoglobulinemia.

Findings:

• The specific type of monoclonal protein significantly influences the type and severity of associated peripheral neuropathy.
• Osteosclerotic myeloma-associated PN may improve with treatment targeting the plasma cell proliferation.
• The efficacy of immunosuppressants and plasmapheresis for certain paraproteinemic neuropathies remains uncertain.

Implications:

• Accurate classification of paraproteinemic neuropathies is essential for appropriate treatment strategies.
• Further research is needed to clarify the role of immunosuppressive therapies in managing these complex conditions.
• This case highlights the diverse neurological manifestations of monoclonal gammopathies and the importance of a multidisciplinary approach.